Director/PDMR Shareholding
14th Nov 2025 11:00
14 November 2025
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that, on 13 November 2025, it was notified of a transaction in the Company's American Depositary Shares (ADSs) by Aradhana Sarin, Executive Director and Chief Financial Officer, as set out below. Two ADSs are equivalent to one of the Company's ordinary shares of $0.25 each.
PDMR | Position | Nature of the transaction | Quantity | Price per Ordinary Share |
Aradhana Sarin | Executive Director and Chief Financial Officer | Sale of ADSs | 15,000 | $88.6345 |
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name | Aradhana Sarin | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Financial Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)
| Name | AstraZeneca PLC | ||||
b)
| LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code | AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
| ||||
b)
| Nature of the transaction
| Sale of AstraZeneca PLC American Depositary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume - Price | Not applicable - single transaction
| ||||
e)
| Date of the transaction
| 12 November 2025 | ||||
f)
| Place of the transaction
| XNAS | ||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company SecretaryAstraZeneca PLC